Anti‑cholinergics’ dementia link questioned

A contrarian take arguing that the widely‑accepted claim that anti‑cholinergic drugs cause long‑term dementia is not well supported: the author disputes the proposed M1→amyloid→tau causal chain, points to statistical and timing issues in PET and cohort studies, and suggests biological tolerance mechanisms could nullify a persistent causal effect. Because these drugs are common (≈25% prevalence), re‑examining the evidence matters for prescribing and regulation. — If correct, the claim would shift clinical advice, regulatory priorities, and public health messaging about a drug class used by millions.